New trial shows felzartamab reduces proteinuria in IgA nephropathy patients

Millie Shah, PhD, corresponding author, Senior Scientist at BiogenThese data further our understanding of the role of CD38+ antibody secreting cells in IgA nephropathy pathogenesis. By directly depleting these cells, felzartamab reduces the cellular drivers of disease and has the potential for durable clinical benefit without continuous dosing, potentially lowering patient burden and offering improved tolerability."

Study: "Felzartamab durably reduces disease relevant biomarkers through targeting of CD38+ plasma cells and plasmablasts, the upstream drivers of IgA nephropathy (IgAN)"

Source:

American Society of Nephrology